Condition: Crohn Disease · Sponsor: Janssen Research & Development, LLC
The purpose of this study is to assess how well guselkumab works when compared to risankizumab in participants with moderately to severely active Crohn's Disease (CD; a long-term condition causing severe inflammation of the intestinal tract).
This description comes directly from the study's public registry record.
Study Contact · 844-434-4210 · Participate-In-This-Study1@its.jnj.com
Always discuss trial participation with your own doctor first.
| Digestive Health Specialists of the Southeast | Dothan, Alabama, United States | Recruiting |
| East View Medical Research | Mobile, Alabama, United States | Recruiting |
| Clinnova Research | Anaheim, California, United States | Recruiting |
| United Gastroenterologists | Los Alamitos, California, United States | Recruiting |
| TLC Clinical Research Inc | Los Angeles, California, United States | Recruiting |
| Hoag Memorial Hospital | Newport Beach, California, United States | Suspended |
| Medical Associates Research Group, Inc. | San Diego, California, United States | Recruiting |
| Peak Gastroenterology Associates | Colorado Springs, Colorado, United States | Recruiting |
| Medical Research Center of Connecticut | Hamden, Connecticut, United States | Recruiting |
| Green Leaf Clinical Trials | Jacksonville, Florida, United States | Recruiting |
| Sanchez Clinical Research, Inc | Miami, Florida, United States | Recruiting |
| GCP Clinical Research | Tampa, Florida, United States | Recruiting |
+ 90 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07499232